The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia
The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6Z 1Y6
- Ionis Investigative Site
-
-
Ontario
-
London, Ontario, Canada, N6A 5B7
- Ionis Investigative Site
-
-
Quebec
-
Chicoutimi, Quebec, Canada, G7H 7K9
- Ionis Investigative Site
-
Sainte-Foy, Quebec, Canada, G1V 4M6
- Ionis Investigative Site
-
-
-
-
-
Dijon, France, 21079
- Ionis Investigative Site
-
Marseille, France, 13385
- Ionis Investigative Site
-
Paris, France, 75013
- Ionis Investigative Site
-
Saint Herblain, France
- Ionis Investigative Site
-
-
-
-
-
Berlin, Germany, 13353
- Ionis Investigative Site
-
Dresden, Germany, 01307
- Ionis Investigative Site
-
-
North Rhine-Westphalia
-
Koeln, North Rhine-Westphalia, Germany, 50937
- Ionis Investigative Site
-
-
-
-
-
Utrecht, Netherlands, 3584 CX
- Ionis Investigative Site
-
-
North Holland
-
Amsterdam, North Holland, Netherlands, 1105 AZ
- Ionis Investigative Site
-
-
South Holland
-
Rotterdam, South Holland, Netherlands, 3045 PM
- Ionis Investigative Site
-
-
-
-
-
Manchester, United Kingdom, M23 9LT
- Ionis Investigative Site
-
Peterborough, United Kingdom, PE3 6DA
- Ionis Investigative Site
-
-
-
-
California
-
Encinitas, California, United States, 92024
- Ionis Investigative Site
-
San Francisco, California, United States, 94143
- Ionis Investigative Site
-
-
Florida
-
Boca Raton, Florida, United States, 33434
- Ionis Investigative Site
-
Miami, Florida, United States, 33147
- Ionis Investigative Site
-
-
Illinois
-
Sterling, Illinois, United States, 61081
- Ionis Investigative Site
-
-
Kansas
-
Kansas City, Kansas, United States, 66160
- Ionis Investigative Site
-
-
Maryland
-
Salisbury, Maryland, United States, 73103
- Ionis Investigative Site
-
Towson, Maryland, United States, 21204
- Ionis Investigative Site
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Ionis Investigative Site
-
-
Michigan
-
Grandville, Michigan, United States, 49418
- Ionis Investigative Site
-
-
New York
-
North Massapequa, New York, United States, 11758-1802
- Ionis Investigative Site
-
-
North Carolina
-
Benson, North Carolina, United States, 27504
- Ionis Investigative Site
-
Chapel Hill, North Carolina, United States, 27609
- Ionis Investigative Site
-
Farmville, North Carolina, United States, 27828
- Ionis Investigative Site
-
Greenville, North Carolina, United States, 27834
- Ionis Investigative Site
-
Morrisville, North Carolina, United States, 27560
- Ionis Investigative Site
-
Raleigh, North Carolina, United States, 27612
- Ionis Investigative Site
-
Wilson, North Carolina, United States, 27609
- Ionis Investigative Site
-
Wilson, North Carolina, United States, 27893
- Ionis Investigative Site
-
-
Ohio
-
Cincinnati, Ohio, United States, 45227
- Ionis Investigative Site
-
Kettering, Ohio, United States, 45429
- Ionis Investigative Site
-
Marion, Ohio, United States, 43302
- Ionis Investigative Site
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73103
- Ionis Investigative Site
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Ionis Investigative Site
-
-
Rhode Island
-
Providence, Rhode Island, United States, 02906
- Ionis Investigative Site
-
-
Texas
-
Houston, Texas, United States, 77030
- Ionis Investigative Site
-
-
Utah
-
Salt Lake City, Utah, United States, 84108
- Ionis Investigative Site
-
-
Virginia
-
Norfolk, Virginia, United States, 23510
- Ionis Investigative Site
-
-
Washington
-
Seattle, Washington, United States, 98104
- Ionis Investigative Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Body mass index (BMI) ≤ 45 kg/m2
- Fasting Triglycerides (TG) ≥ 500 mg/dL (≥ 5.7 mmol/L) at Screening.
- If on statin or fibrate, participants must be on stable, labeled dose for at least 3 months prior to screening. Participants not receiving these drugs within 4 weeks prior to screening are also eligible.
Exclusion Criteria:
- Type 1 diabetes mellitus
- Newly diagnosed type 2 diabetes mellitus (within 12 weeks of screening) or HbA1c ≥ 9.0% at Screening
- Acute pancreatitis within 3 months of screening
- Acute Coronary Syndrome within 6 months of screening
- Major surgery within 3 months of screening
- Prior exposure to ISIS 304801
- Have any other conditions in the opinion of the investigator which could interfere with the participant participating in or completing the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
Volanesorsen-matching placebo administered subcutaneously once-weekly for 26 weeks.
|
Volanesorsen-matching placebo administered subcutaneously once-weekly for 26 weeks.
|
|
Experimental: Volanesorsen 300 mg weekly
Volanesorsen 300 mg administered subcutaneously once-weekly for 26 weeks.
|
300 mg volanesorsen administered subcutaneously once-weekly for 26 weeks.
Other Names:
|
|
Experimental: Volanesorsen 300 mg biweekly, post Week 13
Volanesorsen 300 mg administered subcutaneously once-weekly for 13 weeks, then bi-weekly for 13 weeks.
|
300 mg volanesorsen administered subcutaneously once-weekly for 26 weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Percent Change in Fasting Triglycerides (TG) From Baseline to Month 3
Time Frame: Baseline to 3 months
|
Baseline to 3 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Absolute Change in Fasting TG From Baseline to Month 3
Time Frame: Baseline to 3 months
|
Baseline to 3 months
|
|
|
Treatment Response Rate Defined as Participants With Fasting TG ≥ 40% Reduction From Baseline at Month 3
Time Frame: Baseline to 3 months
|
Baseline to 3 months
|
|
|
Percent Change in High-density Lipoprotein-cholesterol (HDL-C) From Baseline
Time Frame: Baseline to 3 months
|
Baseline to 3 months
|
|
|
Treatment Response Rate Defined as Participants With Fasting TG < 150 mg/dL Reduction From Baseline at Month 3
Time Frame: Baseline to 3 months
|
mg/dL = milligrams per deciliter
|
Baseline to 3 months
|
|
Change From Baseline in Homeostasis Model Assessment-estimated Insulin Resistance (HOMA-IR)
Time Frame: Baseline to 3 and 6 months
|
HOMA-IR was calculated using the following formula: fasting insulin micro-international units per millimeter (μIU/mL) x fasting glucose mg/dL]/405.
A negative change from baseline indicates improvement; a positive change from baseline indicates worsening.
|
Baseline to 3 and 6 months
|
|
Change From Baseline in Glycated Hemoglobin (HbA1c) in Type 2 Diabetes Mellitus (T2DM) Participants
Time Frame: Baseline to 3 and 6 months
|
Baseline to 3 and 6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ISIS 304801-CS16
- 2014-003434-93 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.